High-intensity ultrasound for prostate cancer showed strong 10-year results

Share this content:

A large analysis has demonstrated good long-term outcomes for men who had undergone high-intensity focused ultrasound (HIFU) as a treatment for prostate cancer. Although HIFU is not available in the United States, the researchers believe their findings should elevate this investigational procedure to the status of a primary treatment option.

A team led by Roman Ganzer, MD, of the University of Regensburg in Germany, examined data from 2,552 men (mean age 70.1 years) who had undergone Ablatherm HIFU for stage T1-3 prostate cancer and who had at least one prostate-specific antigen (PSA) follow-up test after achieving a PSA nadir. Ablatherm HIFU uses an ultrasound beam to deliver intense, highly localized heat to a very small part of the prostate.

The patients had been followed for 39.6 months (range 3 to 193 months). Prior to treatment, mean PSA was 10.2 ng/mL and median Gleason sum was 6. After HIFU therapy, the median PSA nadir was 0.11 ng/mL, reached at 12.9 weeks. Overall, the majority (83%) of patients had negative biopsies for as long as 10 years posttreatment.

“HIFU provides good biochemical control through 10 years of follow-up with a mild morbidity profile,” wrote Ganzer and associates in the abstract that accompanied their presentation at the annual meeting of the American Urological Association, held May 14-19, 2011, in Washington, DC (www.aua2011.org/abstracts/printpdf.cfm?ID=1004). “These long-term outcomes represent HIFU emerging from investigational status to become a standard primary treatment option.”

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs